Track your comments!
[x]


When you register, comments on your articles and replies to your comments appear here. Register Now!

Sign in to your account
[x]

Not a Scientific Blogging member yet?

Register Now for a Free Scientificblogging.com Account

  • Customize your profile with pictures, banner, a blogroll and more.
  • Leave comments on articles, add other members to your friend lists, chat with people on the site.
  • Write blog posts that can be seen by hundreds of thousands of readers.

It's free and it only takes a minute!

Already a Scientific Blogging member?

Sign In Now

Forgot Your Password?
Banner
Permission Granted To Challenge The High Court Ruling To Restrict Alzheimers' Drugs Access On The NHS
By Anna Ohlden | December 6th 2007 01:30 PM | Print | E-mail | Track Comments

BASINGSTOKE, England, December 6 /PRNewswire/ -- Not for Distribution to US Media

Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the global specialty biopharmaceutical company, confirms that it will continue to act as an interested party in the appeal against the High Court's recent ruling on the process by which the National Institute for Health and Clinical Excellence (NICE) reached its decision on the cost-effectiveness of drugs used in the early stages of Alzheimer's disease.

The High Court's judgment was handed down on 10th August 2007 and was appealed by both Eisai and NICE.

The Court of Appeal has now granted Eisai permission to appeal this decision and is likely to hear the matter in 2008.

NICE current guidance effectively denies access to drugs on the NHS to newly diagnosed patients with mild Alzheimer's disease.

Note to editors:

In the UK and Ireland, Shire markets REMINYL(R) (galantamine hydrobromide) and REMINYL(R) XL (galantamine hydrobromide) acetylcholinesterase inhibitors that are licensed for the symptomatic treatment of mild and moderately severe dementia of the Alzheimer's type.

SHIRE PLC

Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.

For further information on Shire, please visit the Company's website: http://www.shire.com.

For further information please contact: Shire: Jessica Mann, +44-1256-894-280; Public relations: Rhonda Smith, +44-1264-710428, +44-7887-714957